Hugel approved to sell its second botox dose in China
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Hugel got the nod to sell Letybo 100 in China last October. With the addition of 50 Unit, the company is better positioned to meet changing customer needs, while competing with rival brands. Rival botox brands in China are Allergan, Lanzhou Institute of Biological Products, and Ipsen.
Hugel is the only Korean botox license holder in China.
China’s botox treatment market is expected to grow to about 1.75 trillion won ($1.58 billion) in value by 2025.
The Korean company said it aims to achieve a 30 percent market share in China within three years to become a leading botox company.
Initial export products were already shipped in December and February. A launching event took place early this month.
Botulinum toxin is a purified bacterial substance that blocks muscle nerve signals. Hugel’s botox products are available in five doses (50, 100, 150, 200, 300 units) in Korea.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Hugel approved to sell its second botox dose in China - Pulse by Maeil Business News Korea
- Hyundai Mobis unveils LED rear light serving both brake, tail signal - Pulse by Maeil Business News Korea
- Korea’s display, energy stocks on watch on improved Q1 earnings vs year-ago - Pulse by Maeil Business News Korea
- Netmarble acquires U.S. game developer Kung Fu Factory - Pulse by Maeil Business News Korea
- Korea’s FTC embarks on punitive review on Google for antitrust violation - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- ‘20만닉스’ 축포 쐈지만…현금 곳간은 ‘텅텅’
- ‘지역비하’ 피식대학, 구독자 300만 붕괴…20만 명 등 돌렸다(종합)[MK★이슈] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이